Progressive Multiple Sclerosis (MS) and Paraneoplastic CNS Disorders Gait Changes

Overview

About this study

The purpose of this study is to longitudinally measure cognitive performance in patients with multiple sclerosis and progressive immune-mediated neurodegenerative disorders in order to determine the rate of progression, and to establish quantitative functional biomarkers that can be used to measure treatment effectiveness in therapy trials directly targeting progressive immune-mediated neurodegeneration.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Multiple Sclerosis

  • Diagnosed with multiple sclerosis according to the 2017 revised McDonald criteria.
  • Age ≥18 years.

 Physician determined disease progression

  • Patient must be able to walk without a walker for the motion tests (e.g. 25 ft walk)
  • Patient must be enrolled in IRB#08-007846 and actively participating in sample collections.
  • Patient must agree to the lumbar puncture and skin biopsy components of IRB#08-007846.

Progressive Immune-Mediated Neurodegenerative Disorder

  • Age ≥ 18 years.
  • Physician determined disease progression
  • Gait disorder is primarily associated with a seropositive autoimmune CNS disorder.
  • Patient must be able to walk without a walker for the motion tests (e.g. 25 ft walk).
  • Patient must be enrolled in IRB#08-007846 and actively participating in sample collections.
  • Patient must agree to the lumbar puncture and skin biopsy components of IRB#08-007846.

Exclusion Criteria: 

Multiple Sclerosis

  • Unable to have annual clinical MRI.

Progressive Immune-Mediated Neurodegenerative Disorder

  • Unable to have annual clinical MRI.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/22/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sean Pittock, M.D.

Open for enrollment

Contact information:

Center for Multiple Sclerosis and Autoimmune Neurology

DLCMSANResCoor@mayo.edu

More information

Publications

Publications are currently not available